Transmolecular: Brain storm on cancer

Treatments for primary glioma rely on highly invasive surgeries and intensive radiation and chemotherapy. Recurrence after initial therapy is seen in about 98% of patients, and median survival after recurrence for high-grade gliomas is only two to four months. Further complicating the matter is that glioma-specific detection methods are invasive.
Transmolecular Inc. is opportunistically entering this space, based on a serendipitous discovery by co-founder Harald Sontheimer. In his lab at the University of Alabama, Sontheimer found the ion channel probe he

Read the full 805 word article

How to gain access

Continue reading with a
two-week free trial.